This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Aptose Biosciences (APTO) a New Buy Stock
by Zacks Equity Research
Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Assertio (ASRT) Stock Plunges 65% in 3 Months: Here's Why
by Zacks Equity Research
Assertio (ASRT) appears weighed down by the recent leadership transition. The company is also facing challenges with sales of its product franchisee of late.
Are Medical Stocks Lagging Annovis Bio (ANVS) This Year?
by Zacks Equity Research
Here is how Annovis Bio, Inc. (ANVS) and Aptose Biosciences (APTO) have performed compared to their sector so far this year.
Deciphera (DCPH) Rises 90% in the Past 6 Months: Here's Why
by Zacks Equity Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.
Horizon (HZNP) Completes Enrollment in Phase IV TED Study
by Zacks Equity Research
Horizon (HZNP) completes enrollment in the phase IV study evaluating Tepezza for the treatment of thyroid eye disease in patients with a low clinical activity score.
Sanofi's (SNY) Dupixent Gets FDA Nod for Prurigo Nodularis
by Zacks Equity Research
The FDA approves Sanofi (SNY) and its partner Regeneron's Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis.
Merck's (MRK) Keytruda Gets Four New Approvals in Japan
by Zacks Equity Research
The Ministry of Health, Labour and Welfare approves Merck's (MRK) anti-PD-1 therapy, Keytruda, for four new cancer indications in Japan.
Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223
by Zacks Equity Research
Seagen (SGEN) signs an exclusive agreement with LAVA Therapeutics to develop and commercialize the latter's preclinical asset, LAVA-1223, targeting EGFR-expressing solid tumors.
Emergent (EBS) Acquires Worldwide Rights to Smallpox Antiviral
by Zacks Equity Research
Emergent (EBS) completes the acquisition of worldwide rights to Tembexa, an FDA-approved smallpox oral antiviral for all ages, from Chimerix.
Evaxion (EVAX) Enrolls First Patient in Phase IIb Melanoma Study
by Zacks Equity Research
Evaxion (EVAX) enrolls the first patient in the phase IIb study evaluating its cancer therapy, EVX-01 in combination with Keytruda, for treating melanoma.
Alnylam's (ALNY) Rare Disease Drug Amvuttra Gets EC Nod
by Zacks Equity Research
The European Commission approves Alnylam's (ALNY) Amvuttra for treating hereditary transthyretin-mediated (hATTR) amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy.
Pacira (PCRX) Gets Positive CHMP View on Exparel Label Expansion
by Zacks Equity Research
The CHMP gives a positive opinion on Pacira's (PCRX) marketed drug Exparel and recommended a marketing authorization for the product to treat postsurgical pain in children aged six years or older.
Seagen's (SGEN) Tukysa Gets FDA Priority Review for New Indication
by Zacks Equity Research
FDA grants priority review to Seagen's (SGEN) sNDA for Tukysa in combination with trastuzumab for previously treated HER2-positive metastatic colorectal cancer. A decision is due on Jan 19, 2023.
Roche's (RHHBY) Vabysmo Gets Approval for nAMD & DME in Europe
by Zacks Equity Research
The European Commission approves Roche's (RHHBY) Vabysmo for treating neovascular or wet age-related macular degeneration and visual impairment due to diabetic macular edema.
Horizon's (HZNP) Phase II Sjogren's Syndrome Study Meets Goal
by Zacks Equity Research
Horizon's (HZNP) phase II study on dazodalibep for treating patients with Sjogren's syndrome meets the primary endpoint.
Acadia's (ACAD) Rett Syndrome Drug NDA Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to Acadia's (ACAD) NDA for trofinetide to treat Rett syndrome. A decision from the regulatory body is due on Mar 12, 2023.
Horizon (HZNP) Gets FDA Nod for Krystexxa's Label Expansion
by Zacks Equity Research
The FDA approves Horizon's (HZNP) sBLA for Krystexxa injection plus methotrexate to help people suffering from uncontrolled gout achieve a complete response to therapy.
5 Beaten-Down Biotech Bets to Bounce Back in 2022
by Indrajit Bandyopadhyay
Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.
BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure
by Zacks Equity Research
BridgeBio's (BBIO) acoramidis fails to meet the primary endpoint of a six-minute walk test in cardiomyopathy patients. However, secondary data demonstrate a favorable trend. The study continues.
Community Health (CYH) Up 64% YTD: More Growth Potential Left?
by Zacks Equity Research
Community Health Systems' (CYH) cost-control initiatives are likely to lower costs to a great extent and boost the bottom line.
Reata (RETA) Falls on Negative Advisory Committee Outcome
by Zacks Equity Research
An FDA advisory committee believes Reata's (RETA) bardoxolone study data does not support the effectiveness of the candidate in slowing the progression of CKD in patients with Alport syndrome.
Implied Volatility Surging for Aptose Biosciences (APTO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aptose Biosciences (APTO) stock based on the movements in the options market lately.
Why Investors Should Hold on to Universal Health (UHS) Stock
by Zacks Equity Research
Universal Health (UHS) can bank on balance sheet strength for future acquisitions to grow its business inorganically.
AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints
by Zacks Equity Research
AzurRx (AZRX) is developing lead pipeline candidate as monotherapy and in combination regimen as potential treatment for exocrine pancreatic insufficiency in patients with cystic fibrosis.